In this series of blog posts, we will visit the implications of co-pay accumulators across the 5 Ps—patients, prescribers, products, pharmacies, and payers—and discuss in more detail the Chutes and Ladders reality that it causes.Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
Phyllis Kidder, PharmD, Principal Consultant, attended the recent PCMA Annual Meeting in Scottsdale and came away with two over-arching themes: First, innovation and disruption in healthcare is here and will accelerate over the next few years. As Mostafa Kamal said “if you are not the disruptor, you are going to be disrupted”. Innovation encompasses technology, which […]Read Full Article
As I write this, I am on my way to the Academy of Managed Care Pharmacy’s Annual Meeting in the Mile High city. This is my second year attending the event as a Blue Fin Group consultant. Last year, I had been at Blue Fin Group for just a week, so I primarily had the perspective […]Read Full Article
Orphan medications can treat populations with as few as one hundred patients or less in the US, and may come with high price tag. Payers and manufacturers are dealing with this dynamic in ways that are both similar and distinct. Phyllis Kidder, Principal Consultant, will speak on the topic of “Orphan and Rare Disease Products and Exclusive Pharmacy Networks” with Bill Roth, Founding Partner, this week at the sPCMA conference in Orlando, FL.Read Full Article